ArticleClinicoEconomics and outcomes research : CEOR2021

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database.

Tsugumi Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.